{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:53:31Z","timestamp":1788666811855,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"GlaxoSmithKline"},{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["18-01-403"],"award-info":[{"award-number":["18-01-403"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03782-1","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:19:09Z","timestamp":1773667149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased soluble CD200 in serum of SLE patients does not reflect disease activity or affect CD200R1 function in T cells"],"prefix":"10.1186","volume":"28","author":[{"given":"Ellen D.","family":"Kaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Limper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"Meyaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"van der Vlist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"9894","key":"3782_CR1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013;382(9894):819\u201331.","journal-title":"Lancet"},{"issue":"1","key":"3782_CR2","doi-asserted-by":"publisher","first-page":"2217737","DOI":"10.1080\/2162402X.2023.2217737","volume":"12","author":"J Fenaux","year":"2023","unstructured":"Fenaux J, Fang X, Huang YM, Melero C, Bonnans C, Lowe EL, et al. 23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function. Oncoimmunology. 2023;12(1):2217737.","journal-title":"Oncoimmunology"},{"issue":"4","key":"3782_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"3782_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3782_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","volume":"5","author":"KPM Suijkerbuijk","year":"2024","unstructured":"Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer. 2024;5(4):557\u201371.","journal-title":"Nat Cancer"},{"issue":"20","key":"3782_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","volume":"388","author":"J Tuttle","year":"2023","unstructured":"Tuttle J, Drescher E, Simon-Campos JA, Emery P, Greenwald M, Kivitz A, et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023;388(20):1853\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"3782_CR7","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1038\/s41467-025-59147-w","volume":"16","author":"A Koester","year":"2025","unstructured":"Koester A, Witcher DR, Lee M, Demarest SJ, Potter S, Werle K, et al. Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study. Nat Commun. 2025;16(1):4082.","journal-title":"Nat Commun"},{"issue":"7","key":"3782_CR8","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.4049\/jimmunol.175.7.4441","volume":"175","author":"I Shiratori","year":"2005","unstructured":"Shiratori I, Yamaguchi M, Suzukawa M, Yamamoto K, Lanier LL, Saito T, et al. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol. 2005;175(7):4441\u20139.","journal-title":"J Immunol"},{"issue":"1","key":"3782_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.176.1.191","volume":"176","author":"MC Jenmalm","year":"2006","unstructured":"Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol. 2006;176(1):191\u20139.","journal-title":"J Immunol"},{"issue":"14","key":"3782_CR10","doi-asserted-by":"publisher","first-page":"7667","DOI":"10.1128\/JVI.78.14.7667-7676.2004","volume":"78","author":"M Foster-Cuevas","year":"2004","unstructured":"Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol. 2004;78(14):7667\u201376.","journal-title":"J Virol"},{"issue":"1","key":"3782_CR11","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-021-22832-7","volume":"12","author":"P Shafiei-Jahani","year":"2021","unstructured":"Shafiei-Jahani P, Helou DG, Hurrell BP, Howard E, Quach C, Painter JD, et al. CD200-CD200R immune checkpoint engagement regulates ILC2 effector function and ameliorates lung inflammation in asthma. Nat Commun. 2021;12(1):2526.","journal-title":"Nat Commun"},{"issue":"2","key":"3782_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1365-2567.2001.01163.x","volume":"102","author":"GJ Wright","year":"2001","unstructured":"Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal\/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology. 2001;102(2):173\u20139.","journal-title":"Immunology"},{"issue":"3","key":"3782_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1034\/j.1600-0897.2003.00086.x","volume":"50","author":"DA Clark","year":"2003","unstructured":"Clark DA, Keil A, Chen Z, Markert U, Manuel J, Gorczynski RM. Placental trophoblast from successful human pregnancies expresses the tolerance signaling molecule, CD200 (OX-2). Am J Reprod Immunol. 2003;50(3):187\u201395.","journal-title":"Am J Reprod Immunol"},{"key":"3782_CR14","doi-asserted-by":"publisher","unstructured":"ChoueiryF, Torok M, Shakya R, Agrawal K, Deems A, Benner B, et al. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J Immunother Cancer. 2020;8(1):e000189. https:\/\/doi.org\/10.1136\/jitc-2019-000189.","DOI":"10.1136\/jitc-2019-000189"},{"issue":"3","key":"3782_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/sj.leu.2404559","volume":"21","author":"A Tonks","year":"2007","unstructured":"Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21(3):566\u20138.","journal-title":"Leukemia"},{"issue":"13","key":"3782_CR16","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","volume":"108","author":"J Moreaux","year":"2006","unstructured":"Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108(13):4194\u20137.","journal-title":"Blood"},{"issue":"704","key":"3782_CR17","doi-asserted-by":"publisher","first-page":"eabb4324","DOI":"10.1126\/scisignal.abb4324","volume":"14","author":"M van der Vlist","year":"2021","unstructured":"van der Vlist M, Ramos MIP, van den Hoogen LL, Hiddingh S, Timmerman LM, de Hond TAP, et al. Signaling by the inhibitory receptor CD200R is rewired by type I interferon. Sci Signal. 2021;14(704):eabb4324.","journal-title":"Sci Signal"},{"issue":"3","key":"3782_CR18","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar3853","volume":"14","author":"Y Li","year":"2012","unstructured":"Li Y, Zhao LD, Tong LS, Qian SN, Ren Y, Zhang L, et al. Aberrant CD200\/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res Ther. 2012;14(3):R123.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"3782_CR19","doi-asserted-by":"publisher","first-page":"e0230621","DOI":"10.1371\/journal.pone.0230621","volume":"15","author":"AA Ismail","year":"2020","unstructured":"Ismail AA, Donia HM, Ghatesh HM, Farid CI. CD200\/CD200 receptor axis in psoriasis vulgaris. PLoS ONE. 2020;15(3):e0230621.","journal-title":"PLoS ONE"},{"key":"3782_CR20","doi-asserted-by":"publisher","unstructured":"HaJW, Chung J, Yoon T, Park YB, Lee SW. Clinical utility of serum sCD200\/sCD200R ratios in predicting current activity of antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Med. 2025;14(8):2720. https:\/\/doi.org\/10.3390\/jcm14082720.","DOI":"10.3390\/jcm14082720"},{"issue":"5","key":"3782_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/1756-185X.13810","volume":"23","author":"TT Liu","year":"2020","unstructured":"Liu TT, Zeng XP, Gu ML, Deng AM. Increased CD200 levels in peripheral blood mononuclear cells of patients with primary Sjogren\u2019s syndrome. Int J Rheum Dis. 2020;23(5):654\u201360.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"3782_CR22","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.molimm.2007.07.013","volume":"45","author":"ES Rijkers","year":"2008","unstructured":"Rijkers ES, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol. 2008;45(4):1126\u201335.","journal-title":"Mol Immunol"},{"issue":"9","key":"3782_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European league against Rheumatism\/American College of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3782_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3782_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3782_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology\/European League against rheumatism classification criteria for primary sjogren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"3782_CR27","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/art.20798","volume":"50","author":"KA Kirou","year":"2004","unstructured":"Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50(12):3958\u201367.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3782_CR28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, van Helden-Meeuwsen CG, van de Merwe JP, van Daele PL, Dalm VA, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"3782_CR29","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-12-1390","volume":"72","author":"KK Wong","year":"2012","unstructured":"Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res. 2012;72(19):4931\u201343.","journal-title":"Cancer Res"},{"issue":"7","key":"3782_CR30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/0267659114558286","volume":"30","author":"D Holmannova","year":"2015","unstructured":"Holmannova D, Kolackova M, Mandak J, Kunes P, Holubcova Z, Krejsek J, et al. Inhibitory CD200R and proapoptotic CD95\/CD95L molecules on innate immunity cells are modulated by cardiac surgery. Perfusion. 2015;30(7):543\u201355.","journal-title":"Perfusion"},{"issue":"4","key":"3782_CR31","doi-asserted-by":"publisher","first-page":"e0152073","DOI":"10.1371\/journal.pone.0152073","volume":"11","author":"KK Wong","year":"2016","unstructured":"Wong KK, Zhu F, Khatri I, Huo Q, Spaner DE, Gorczynski RM. Characterization of CD200 ectodomain shedding. PLoS ONE. 2016;11(4):e0152073.","journal-title":"PLoS ONE"},{"issue":"12","key":"3782_CR32","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1136\/annrheumdis-2018-213497","volume":"77","author":"LL van den Hoogen","year":"2018","unstructured":"van den Hoogen LL, van Roon JAG, Mertens JS, Wienke J, Lopes AP, de Jager W, et al. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2018;77(12):1810\u20134.","journal-title":"Ann Rheum Dis"},{"key":"3782_CR33","unstructured":"Limper M. PRediction Of Flares In Lupus With autoantibodiEs and Chemokines (PROFILE): ClinicalTrials.gov; 2022 [NCT04951427]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04951427?locStr=Utrecht,%20Netherlands&country=NL&state=Utrecht&city=Utrecht&cond=SLE&rank=6."},{"key":"3782_CR34","doi-asserted-by":"publisher","unstructured":"SagawaR, Sakata S, Gong B, Seto Y, Takemoto A, Takagi S, et al. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight. 2022;7(1):e153323. https:\/\/doi.org\/10.1172\/jci.insight.153323.","DOI":"10.1172\/jci.insight.153323"},{"issue":"4","key":"3782_CR35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/rheumatology\/keu362","volume":"54","author":"Y Ren","year":"2015","unstructured":"Ren Y, Yang B, Yin Y, Leng X, Jiang Y, Zhang L, et al. Aberrant CD200\/CD200R1 expression and its potential role in Th17 cell differentiation, chemotaxis and osteoclastogenesis in rheumatoid arthritis. Rheumatology (Oxford). 2015;54(4):712\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3782_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00011-014-0716-6","volume":"63","author":"S Gao","year":"2014","unstructured":"Gao S, Hao B, Yang XF, Chen WQ. Decreased CD200R expression on monocyte-derived macrophages correlates with Th17\/Treg imbalance and disease activity in rheumatoid arthritis patients. Inflamm Res. 2014;63(6):441\u201350.","journal-title":"Inflamm Res"},{"issue":"6","key":"3782_CR37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916934.2015.1037441","volume":"48","author":"D Li","year":"2015","unstructured":"Li D, Guo B, Wu H, Tan L, Chang C, Lu Q. Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity. 2015;48(6):353\u201361.","journal-title":"Autoimmunity"},{"issue":"2","key":"3782_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41584-019-0356-x","volume":"16","author":"A Sharabi","year":"2020","unstructured":"Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020;16(2):100\u201312.","journal-title":"Nat Rev Rheumatol"},{"key":"3782_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3389\/fimmu.2020.01027","volume":"11","author":"J Shan","year":"2020","unstructured":"Shan J, Jin H, Xu Y. T Cell Metabolism: A New Perspective on Th17\/Treg Cell Imbalance in Systemic Lupus Erythematosus. Front Immunol. 2020;11:1027.","journal-title":"Front Immunol"},{"issue":"73","key":"3782_CR40","doi-asserted-by":"publisher","first-page":"eabm3723","DOI":"10.1126\/sciimmunol.abm3723","volume":"7","author":"CM Orr","year":"2022","unstructured":"Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, et al. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci Immunol. 2022;7(73):eabm3723.","journal-title":"Sci Immunol"},{"issue":"8","key":"3782_CR41","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.4049\/jimmunol.0901531","volume":"183","author":"R Mihrshahi","year":"2009","unstructured":"Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol. 2009;183(8):4879\u201386.","journal-title":"J Immunol"},{"issue":"11","key":"3782_CR42","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.4049\/jimmunol.173.11.6786","volume":"173","author":"S Zhang","year":"2004","unstructured":"Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173(11):6786\u201393.","journal-title":"J Immunol"},{"key":"3782_CR43","doi-asserted-by":"crossref","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11(0 11):S37\u201346.","DOI":"10.1002\/acr.20572"},{"issue":"7","key":"3782_CR44","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.leukres.2013.04.014","volume":"37","author":"T Twito","year":"2013","unstructured":"Twito T, Chen Z, Khatri I, Wong K, Spaner D, Gorczynski R. Ectodomain shedding of CD200 from the B-CLL cell surface is regulated by ADAM28 expression. Leuk Res. 2013;37(7):816\u201321.","journal-title":"Leuk Res"},{"key":"3782_CR45","doi-asserted-by":"publisher","unstructured":"MorganHJ, Rees E, Lanfredini S, Powell KA, Gore J, Gibbs A, et al. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. J Clin Invest. 2022;132(21):e150750. https:\/\/doi.org\/10.1172\/JCI150750.","DOI":"10.1172\/JCI150750"},{"key":"3782_CR46","doi-asserted-by":"publisher","unstructured":"RutscheD, Michalak-Micka K, Zielinska D, Moll H, Moehrlen U, Biedermann T, et al. The role of CD200-CD200 receptor in human blood and lymphatic endothelial cells in the regulation of skin tissue inflammation. Cells. 2022;11(6):1055. https:\/\/doi.org\/10.3390\/cells11061055.","DOI":"10.3390\/cells11061055"},{"issue":"7","key":"3782_CR47","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1182\/blood-2003-09-3184","volume":"103","author":"MD Rosenblum","year":"2004","unstructured":"Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, et al. CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. Blood. 2004;103(7):2691\u20138.","journal-title":"Blood"},{"issue":"1","key":"3782_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nrc3171","volume":"12","author":"MP Chao","year":"2011","unstructured":"Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer. 2011;12(1):58\u201367.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3782_CR49","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.179.4.1317","volume":"179","author":"LA Casciola-Rosen","year":"1994","unstructured":"Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179(4):1317\u201330.","journal-title":"J Exp Med"},{"issue":"12","key":"3782_CR50","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716\u201330.","journal-title":"Nat Rev Rheumatol"},{"key":"3782_CR51","doi-asserted-by":"publisher","first-page":"103278","DOI":"10.1016\/j.jaut.2024.103278","volume":"147","author":"L Yuan","year":"2024","unstructured":"Yuan L, Wang Y, Shen X, Ma F, Wang J, Yan F. Soluble form of immune checkpoints in autoimmune diseases. J Autoimmun. 2024;147:103278.","journal-title":"J Autoimmun"},{"issue":"44","key":"3782_CR52","doi-asserted-by":"publisher","first-page":"E9338","DOI":"10.1073\/pnas.1710358114","volume":"114","author":"CB Carbone","year":"2017","unstructured":"Carbone CB, Kern N, Fernandes RA, Hui E, Su X, Garcia KC, et al. In vitro reconstitution of T cell receptor-mediated segregation of the CD45 phosphatase. Proc Natl Acad Sci U S A. 2017;114(44):E9338\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3782_CR53","doi-asserted-by":"publisher","unstructured":"Lippert AH, Paluch C, Gaglioni M, Vuong MT, Mccoll J, Jenkins E, et al. Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases. Immunity. 2024;57(2):256-270.e10. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.007.","DOI":"10.1016\/j.immuni.2024.01.007"},{"issue":"3","key":"3782_CR54","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/TP.0b013e3182754c30","volume":"95","author":"R Gorczynski","year":"2013","unstructured":"Gorczynski R, Chen Z, Khatri I, Yu K. sCD200 present in mice receiving cardiac and skin allografts causes immunosuppression in vitro and induces Tregs. Transplantation. 2013;95(3):442\u20137.","journal-title":"Transplantation"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03782-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03782-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:02:11Z","timestamp":1776909731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03782-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3782"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03782-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The UMCU medical ethical committee (METC): PRediction Of Flares In Lupus with autoantibodiEs and chemokines (PROFILE), #21\u2013369; and the IFN-study, #13\u2013697.UMCU Biobank Ethical Committee approved the UMC Utrecht Mini Donor Service (#18\u2013774).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read the manuscript and consented with publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L.M. obtained consultancy fees from Eli Lilly and Company, Third Rock Ventures, and AbbVie, all paid to UMC Utrecht. M.L obtained consultancy fees from Glaxo Smith Kline, Thermo Fisher, Otsuka and AstraZeneca, all paid to the UMC Utrecht. L.M., M.L and M.V. did not receive personal fees or other personal benefits. Our research laboratory at University Medical Center (UMC) Utrecht received research funding from NextCure, NGM Biopharmaceuticals, Boehringer Ingelheim, and argenx. L.M. and M.V. have a patent pending on the discovery of putative inhibitory receptors. E.D.K and F.V. do not have competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}